News
Jan 7
2008
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
Jan 7
2008
MOUNTAIN VIEW, Calif., Jan. 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, today announced it has initiated a Phase 3 clinical trial evaluating Unit Dose Budesonide (UDB), the company's proprietary nebulized version of budesonide, for the potential treatment of pediatric asthma.
READ MORE about MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma